Latest news with #LigaChemBiosciences
Yahoo
08-08-2025
- Business
- Yahoo
August 2025's Asian Stock Picks For Estimated Value Opportunities
As global trade tensions and economic uncertainties weigh on markets, Asian indices have experienced mixed performances, with China's economy showing signs of slowing growth and Japan's market facing renewed pressure from international developments. In this environment, identifying undervalued stocks in Asia could present potential opportunities for investors seeking to capitalize on discrepancies between market price and intrinsic value. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Xiaocaiyuan International Holding (SEHK:999) HK$10.27 HK$20.32 49.5% Xi'an NovaStar Tech (SZSE:301589) CN¥157.17 CN¥311.32 49.5% Wuxi Zhenhua Auto PartsLtd (SHSE:605319) CN¥33.56 CN¥65.39 48.7% NEOWIZ (KOSDAQ:A095660) ₩26950.00 ₩52750.47 48.9% LigaChem Biosciences (KOSDAQ:A141080) ₩149100.00 ₩288985.41 48.4% Hibino (TSE:2469) ¥2440.00 ¥4729.93 48.4% Heartland Group Holdings (NZSE:HGH) NZ$0.80 NZ$1.58 49.5% GEM (SZSE:002340) CN¥6.53 CN¥12.93 49.5% cottaLTD (TSE:3359) ¥444.00 ¥871.79 49.1% Andes Technology (TWSE:6533) NT$277.50 NT$541.97 48.8% Click here to see the full list of 266 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. We're going to check out a few of the best picks from our screener tool. LigaChem Biosciences Overview: LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing medicines for unmet medical needs and has a market capitalization of approximately ₩5.41 trillion. Operations: The company's revenue is primarily derived from its Pharmaceutical Business segment, which generated approximately ₩20.86 billion, and its New Drug Research and Development segment, contributing around ₩125.56 billion. Estimated Discount To Fair Value: 48.4% LigaChem Biosciences is trading at ₩149,100, significantly below its estimated fair value of ₩288,985.41. Despite recent share price volatility and low forecasted return on equity (7.4%), the company has become profitable this year with earnings expected to grow 50.5% annually, outpacing the KR market's 22.2%. Recent developments include a completed share buyback and ongoing Phase 1 trials for LNCB74 targeting advanced solid tumors, highlighting potential growth avenues amid robust cash flow prospects. Upon reviewing our latest growth report, LigaChem Biosciences' projected financial performance appears quite optimistic. Click to explore a detailed breakdown of our findings in LigaChem Biosciences' balance sheet health report. Beijing Zhong Ke San Huan High-Tech Overview: Beijing Zhong Ke San Huan High-Tech Co., Ltd. operates in the high-tech sector, focusing on the production and development of advanced magnetic materials, with a market cap of CN¥16.90 billion. Operations: Beijing Zhong Ke San Huan High-Tech Co., Ltd. generates its revenue primarily from the production and development of advanced magnetic materials. Estimated Discount To Fair Value: 25.1% Beijing Zhong Ke San Huan High-Tech is currently trading at CNY 14.04, well below its estimated fair value of CNY 18.75. The company reported a turnaround with net income of CNY 43.99 million for the first half of 2025, compared to a loss last year, indicating improved financial health despite recent sales decline. Earnings are forecasted to grow significantly at 46.8% annually over the next three years, surpassing market averages and suggesting strong cash flow potential amidst low return on equity forecasts. The analysis detailed in our Beijing Zhong Ke San Huan High-Tech growth report hints at robust future financial performance. Delve into the full analysis health report here for a deeper understanding of Beijing Zhong Ke San Huan High-Tech. Silergy Overview: Silergy Corp. designs, manufactures, and sells integrated circuit products and related technical services in China and internationally, with a market cap of NT$129.60 billion. Operations: The company's revenue is primarily derived from its semiconductors segment, which generated NT$18.71 billion. Estimated Discount To Fair Value: 33% Silergy is trading at NT$335, significantly below its estimated fair value of NT$500.22, highlighting potential undervaluation based on cash flows. The company reported strong Q1 2025 results with net income rising to TWD 358.56 million from TWD 78.01 million a year ago, suggesting robust financial performance despite a low forecasted return on equity of 14.9% in three years. Recent board changes may influence strategic direction positively amidst expected significant earnings growth of 34.1% annually over the next three years. The growth report we've compiled suggests that Silergy's future prospects could be on the up. Unlock comprehensive insights into our analysis of Silergy stock in this financial health report. Next Steps Take a closer look at our Undervalued Asian Stocks Based On Cash Flows list of 266 companies by clicking here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Curious About Other Options? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A141080 SZSE:000970 and TWSE:6415. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
30-05-2025
- Business
- Yahoo
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers. A scientist in a lab researching the biology of a cancer cell. The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC's target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy. According to NextCure, Inc. (NASDAQ:NXTC)'s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the 'Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology' session. NXTC closed nearly 6% higher on May 29. While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
30-05-2025
- Business
- Yahoo
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers. A scientist in a lab researching the biology of a cancer cell. The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC's target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy. According to NextCure, Inc. (NASDAQ:NXTC)'s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the 'Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology' session. NXTC closed nearly 6% higher on May 29. While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
30-05-2025
- Business
- Yahoo
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers. A scientist in a lab researching the biology of a cancer cell. The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC's target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy. According to NextCure, Inc. (NASDAQ:NXTC)'s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the 'Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology' session. NXTC closed nearly 6% higher on May 29. While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-05-2025
- Business
- Yahoo
3 Asian Stocks Estimated To Be Trading Below Intrinsic Value In May 2025
As global markets experience volatility amid renewed tariff threats and fluctuating economic indicators, Asian stock markets are also navigating these challenging conditions. In such an environment, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on market inefficiencies. Name Current Price Fair Value (Est) Discount (Est) Pansoft (SZSE:300996) CN¥14.27 CN¥28.25 49.5% Livero (TSE:9245) ¥1694.00 ¥3383.28 49.9% Range Intelligent Computing Technology Group (SZSE:300442) CN¥43.44 CN¥85.01 48.9% Devsisters (KOSDAQ:A194480) ₩38100.00 ₩76151.09 50% Zhuhai CosMX Battery (SHSE:688772) CN¥13.46 CN¥26.77 49.7% Kolmar Korea (KOSE:A161890) ₩84600.00 ₩168491.07 49.8% Kanto Denka Kogyo (TSE:4047) ¥832.00 ¥1644.44 49.4% KG Mobilians (KOSDAQ:A046440) ₩4255.00 ₩8288.55 48.7% SpiderPlus (TSE:4192) ¥460.00 ¥919.15 50% Cosmax (KOSE:A192820) ₩209500.00 ₩407469.70 48.6% Click here to see the full list of 298 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Overview: LigaChem Biosciences Inc. is a clinical stage biopharmaceutical company focused on discovering and developing medicines for unmet medical needs, with a market cap of ₩4 trillion. Operations: The company generates revenue from two main segments: Pharmaceutical Business, contributing ₩20.54 billion, and New Drug Research and Development, accounting for ₩105.36 billion. Estimated Discount To Fair Value: 33.3% LigaChem Biosciences is trading at ₩110,400, considerably below its estimated fair value of ₩165,629.14. Despite recent negative sales figures, the company turned profitable with a net income of KRW 7.8 billion in 2024 and forecasts significant earnings growth of 58.9% annually over three years. The strategic alliance with WuXi XDC enhances ADC development capabilities, potentially boosting cash flows further as LigaChem capitalizes on this partnership for innovative therapies. Insights from our recent growth report point to a promising forecast for LigaChem Biosciences' business outlook. Unlock comprehensive insights into our analysis of LigaChem Biosciences stock in this financial health report. Overview: RemeGen Co., Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States, with a market cap of approximately HK$31.70 billion. Operations: RemeGen's revenue is primarily derived from its biopharmaceutical research, service, production, and sales segment, totaling CN¥1.91 billion. Estimated Discount To Fair Value: 34.1% RemeGen's stock, trading at HK$51.2, is significantly undervalued compared to its estimated fair value of HK$77.67. The company's revenue growth forecast of 23.2% annually outpaces the Hong Kong market average and it is expected to become profitable within three years. Recent advancements include successful clinical trials for disitamab vedotin, enhancing its therapeutic portfolio and potential cash flows despite a volatile share price and ongoing net losses reported in Q1 2025 earnings results. Our earnings growth report unveils the potential for significant increases in RemeGen's future results. Click here to discover the nuances of RemeGen with our detailed financial health report. Overview: Chugin Financial Group Inc., with a market cap of ¥307.82 billion, operates through its subsidiary The Chugoku Bank, Limited to offer a range of financial services to both corporate and individual clients in Japan. Operations: The company's revenue segments include ¥11.73 billion from the Banking segment, ¥14.54 million from the Lease segment, and ¥3.97 million from the Securities Industry. Estimated Discount To Fair Value: 19.7% Chugin Financial Group, Inc. is trading at ¥1,720.5, below its estimated fair value of ¥2,141.51. Forecasted revenue growth of 33.1% annually surpasses Japan's market average significantly, while earnings are expected to grow at 14.3% per year. The company announced a share buyback program and increased dividends for fiscal 2026 to enhance shareholder returns despite recent share price volatility and a low return on equity forecast of 7%. In light of our recent growth report, it seems possible that Chugin Financial GroupInc's financial performance will exceed current levels. Click here and access our complete balance sheet health report to understand the dynamics of Chugin Financial GroupInc. Navigate through the entire inventory of 298 Undervalued Asian Stocks Based On Cash Flows here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A141080 SEHK:9995 and TSE:5832. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
